èšåºæ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ããã¢ãããµã»ã»ã©ãã¥ãŒãã£ã¯ã¹ç€Ÿã¯ãè
«çåŠããã³ææçã®åéã§å»è¬åã®çºèŠãšéçºãè¡ã£ãŠããŸããå瀟ã®äž»åããã°ã©ã ã¯ãä¹³ããã®æ²»çãšäºé²ãç®çãšãã第2çžèšåºè©Šéšãè¡ãããŠããã¿ã¢ãã·ãã§ã³ã®æŽ»æ§ä»£è¬ç©ã§ãããšã³ããã·ãã§ã³ã§ãããŸããCOVID-19ãšèšºæãããæ£è
ã«çµéŒ»æäžããããã®ç¬èªã®åè£è¬AT-301ãCOVID-19æ£è
ã®èºæ©èœãæ¹åããåè£è¬AT-H201ãããã³ä¹³ããæ²»çã®ããã®å
ç«çæ³/ãã¡ã©æåå容äœçæ³ããã°ã©ã ãéçºããŠããŸããã¢ãããµã»ã»ã©ãã¥ãŒãã£ã¯ã¹ç€Ÿã¯ãä¹³ããã®æœåšçãªæ²»çè¬ãšããŠãµã€ãã«ã€ã³ã³ãŒãã£ã³ã°ãããããç²åã®ç ç©¶ãæ¯æŽããããããããã¡ãŒããŒããç ç©¶æãšç ç©¶å¥çŽãçµãã§ããŸããå瀟ã¯ä»¥åã¯Atossa Genetics Inc.ãšããŠç¥ãããŠããŸãããã2020幎1æã«Atossa Therapeutics, Inc.ã«ç€Ÿåã倿ŽããŸãããAtossa Therapeutics, Inc.ã¯2008幎ã«èšç«ãããã¯ã·ã³ãã³å·ã·ã¢ãã«ã«æ¬ç€Ÿã眮ããŠããŸãã